Ignite Creation Date:
2025-12-25 @ 4:41 AM
Ignite Modification Date:
2026-03-06 @ 10:06 AM
Study NCT ID:
NCT04324918
Status:
COMPLETED
Last Update Posted:
2020-03-27
First Post:
2020-02-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis
Sponsor:
Hanmi Pharmaceutical Company Limited
Organization:
Study Overview
Official Title:
Efficacy and Safety of HCP1102 in Patients With Perennial Allergic Rhinitis : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Efficacy and safety of HCP1102 in patients with perennial allergic rhinitis :
A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial
A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: